One arrow and two carvings! The new prostate cancer drug inhibits both carcinogens

According to a new report by researchers at the University of Houston, they have developed a new treatment for highly malignant and often fatal prostate cancer, and they have found a new drug that inhibits two major signaling path paths in prostate cancer. Dr. Ruiwen Zhang, an honorary professor of drug development at Robert L. Boblitt, completed the study with Dr. Wei Wang, an associate professor of pharmacy, in the journal Cancer Research.
" prostate cancer treatment is in urgent need of new and effective safety drugs. Our findings represent a major advance in cancer research. Dr. Zhang said. Most drugs can only target one target, and the compounds we found can target two genes associated with cancer at the same time. "This is going to be a new class of drugs for prostate cancer, representing a new direction for drug development.
prostate cancer is characterized by early metastasis and low response to chemotherapy. The clinical benefits to patients are general, but are still the main treatment for advanced prostate cancer. Although the researchers tested a combination therapy for a variety of combinations of gistabin and other drugs, only three are currently FDA-approved, and almost no one can significantly prolong the survival of prostate cancer patients. The removal of substitlis and immunotherapy are also clinically promising treatments for advanced prostate cancer, but the efficacy of them is not clear.
two cancer-causing genes in the study were the activation of T-factors 1 (nuclear factor of activated T cells1, NFAT1) and mouse bi-microgene 2 (murine double minute 2, MDM2), a gene that regulates the tumor suppressor gene p53. If the anti-cancer gene p53 does not exist, MDM2 itself can cause cancer. NFAT1 can raise MDM2 expression to further promote tumor growth.
"We developed a compound called MA242 that can remove both proteins at the same time, thereby enhancing the specificity and efficiency of killing cancer cells. "Zhang said." In our molecular simulation study, MA242 is a powerful double inhibitor. "Although synthetic molecules, they are based on a sponge.
high expression of MDM2 and NFAT1 in prostate cancer patients, making these genes targets for the treatment of prostate cancer. Numerous studies have found that reducing MDM2 can slow tumor growth and progress. Zhang says healthy human expression levels of MDM2 and NFAT1 are low, but diet, nutrition and the environment can lead to high expression of both genes. In their past published studies, they found that natural foods or products, such as cured or even treated with cancer, such as orchids, soy, green tea and turmeric. (Bio Valley)